<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327112456312</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327112456312</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Spectral analysis of thioacetamide-induced electroencephalographic changes in rats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mladenović</surname>
<given-names>D</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112456312">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hrnčić</surname>
<given-names>D</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112456312">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rašić-Marković</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112456312">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Puškaš</surname>
<given-names>N</given-names>
</name>
<xref ref-type="aff" rid="aff3-0960327112456312">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Petrovich</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff4-0960327112456312">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Stanojlović</surname>
<given-names>O</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112456312">2</xref>
<xref ref-type="corresp" rid="corresp1-0960327112456312"/>
</contrib>
</contrib-group>
<aff id="aff1-0960327112456312">
<label>1</label>Institute of Pathophysiology, Faculty of Medicine, University of Belgrade, Dr Subotica 9 Belgrade, Serbia</aff>
<aff id="aff2-0960327112456312">
<label>2</label>Institute of Medical Physiology “Richard Burian”, Faculty of Medicine, University of Belgrade, Višegradska 26/II, Belgrade, Serbia</aff>
<aff id="aff3-0960327112456312">
<label>3</label>Institute of Histology and Embryology, Faculty of Medicine, University of Belgrade, Višegradska 26, Belgrade, Serbia</aff>
<aff id="aff4-0960327112456312">
<label>4</label>Laboratory of Molecular Biology and Endocrinology, Vinča Institute of Nuclear Sciences, University of Belgrade, Serbia</aff>
<author-notes>
<corresp id="corresp1-0960327112456312">O Stanojlović, Institute of Medical Physiology “Richard Burian”, Faculty of Medicine, University of Belgrade, Višegradska 26/II, 11000 Belgrade, Serbia Email: <email>solja@afrodita.rcub.bg.ac.rs</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>32</volume>
<issue>1</issue>
<fpage>90</fpage>
<lpage>100</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Thioacetamide (TAA) is widely used as a model of hepatic encephalopathy (HE). The aim of our study was to investigate the effects of TAA on electroencephalographic (EEG) changes in rats and to compare them with human HE. Male Wistar rats were divided into groups: (1) saline-treated group and (2) TAA-treated groups: TAA<sub>300</sub> (300 mg/kg), TAA<sub>600</sub> (600 mg/kg), and TAA<sub>900</sub> (900 mg/kg). Daily dose of TAA (300 mg/kg) was administered intraperitoneally once (TAA<sub>300</sub>), twice (TAA<sub>600</sub>), or thrice (TAA<sub>900</sub>) in subsequent days. EEG changes were recorded about 24 h after the last dose of TAA. Absolute and relative power density in alpha bands were significantly higher in TAA<sub>300</sub> versus control group. In TAA<sub>300</sub>, absolute beta power density was higher and relative beta power density was lower versus control group. Absolute alpha, theta, delta, and relative theta power were significantly lower, while relative power in delta band was significantly higher in TAA<sub>900</sub> versus control group (<italic>p</italic> &lt; 0.01). In conclusion, decrease in EEG voltage with an increase in delta relative power, which correspond to the EEG manifestations of severe HE in humans, was observed in TAA<sub>900</sub> group. Electrical activity in TAA<sub>300</sub> group correlates with mild HE in humans.</p>
</abstract>
<kwd-group>
<kwd>Thioacetamide</kwd>
<kwd>hepatic encephalopathy</kwd>
<kwd>EEG</kwd>
<kwd>spectral analysis</kwd>
<kwd>rats</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327112456312">
<title>Introduction</title>
<p>Hepatic encephalopathy (HE) represents a neuropsychiatric syndrome that appears as a result of acute or chronic liver failure.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112456312">1</xref>
</sup> The pathogenesis of HE is not completely understood. Hyperammonemia has a central role in the pathogenetic mechanisms of HE, while the astrocytes are the principal target of ammonia neurotoxicity.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112456312">2</xref>
<xref ref-type="bibr" rid="bibr3-0960327112456312"/>–<xref ref-type="bibr" rid="bibr4-0960327112456312">4</xref>
</sup> Acute hyperammonemia induces astrocyte swelling, cytotoxic brain edema, and an increase in intracranial pressure.<sup>
<xref ref-type="bibr" rid="bibr5-0960327112456312">5</xref>,<xref ref-type="bibr" rid="bibr6-0960327112456312">6</xref>
</sup> In addition, acute increase in ammonia level induces mitochondrial permeability transition, an increase in glutamatergic transmission with excitotoxicity,<sup>
<xref ref-type="bibr" rid="bibr4-0960327112456312">4</xref>
</sup> oxidative stress, increased production of nitric oxide, and central inflammatory process, which were also postulated to contribute to the pathogenesis of acute HE.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112456312">7</xref>,<xref ref-type="bibr" rid="bibr8-0960327112456312">8</xref>
</sup>
</p>
<p>On the other hand, in chronic HE, the dominant morphologic brain lesion is Alzheimer’s type II astrocytosis.<sup>
<xref ref-type="bibr" rid="bibr6-0960327112456312">6</xref>
</sup> Several mechanisms have been proposed to mediate neurotoxic effects of ammonia in chronic HE, including changes in neurotransmission with predominance of gamma-aminobutyric acid (GABA)ergic transmission,<sup>
<xref ref-type="bibr" rid="bibr9-0960327112456312">9</xref>
</sup> increased synthesis of neurosteroids<sup>
<xref ref-type="bibr" rid="bibr10-0960327112456312">10</xref>
</sup> and changes in cellular energetics. Immune dysregulation has also been proposed to contribute to the pathogenesis of HE.<sup>
<xref ref-type="bibr" rid="bibr11-0960327112456312">11</xref>
</sup>
</p>
<p>Thioacetamide (TAA), a sulfur-containing substance used in metallurgy, rubber and paper industries, and also as a pesticide, is frequently used for induction of acute or chronic liver failure.<sup>
<xref ref-type="bibr" rid="bibr12-0960327112456312">12</xref>
<xref ref-type="bibr" rid="bibr13-0960327112456312"/>–<xref ref-type="bibr" rid="bibr14-0960327112456312">14</xref>
</sup> It exerts hepatotoxic, carcinogenic, and neurotoxic effects.<sup>
<xref ref-type="bibr" rid="bibr12-0960327112456312">12</xref>,<xref ref-type="bibr" rid="bibr15-0960327112456312">15</xref>,<xref ref-type="bibr" rid="bibr16-0960327112456312">16</xref>
</sup>
</p>
<p>Currently, there is no ideal experimental model of HE. One of the criteria an ideal model should fulfill is the correlation between electroencephalographic (EEG) changes in the model and in humans.<sup>
<xref ref-type="bibr" rid="bibr17-0960327112456312">17</xref>
</sup> Electroencephalography represents a key method in the evaluation of HE.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112456312">18</xref>
</sup> It can complement neurological findings to provide evidence of HE in patients with preserved consciousness or to exclude some other conditions that may disturb the consciousness. In addition, electroencephalograph is useful for the follow-up of the course of HE as well as of therapeutical procedures.<sup>
<xref ref-type="bibr" rid="bibr19-0960327112456312">19</xref>
</sup> Various methods of electrophysiological analysis in HE were proposed in previous studies. These analyses include visual EEG assessment,<sup>
<xref ref-type="bibr" rid="bibr20-0960327112456312">20</xref>
<xref ref-type="bibr" rid="bibr21-0960327112456312"/>–<xref ref-type="bibr" rid="bibr22-0960327112456312">22</xref>
</sup> spectral analysis,<sup>
<xref ref-type="bibr" rid="bibr21-0960327112456312">21</xref>
<xref ref-type="bibr" rid="bibr22-0960327112456312"/>–<xref ref-type="bibr" rid="bibr23-0960327112456312">23</xref>
</sup> artificial neural networks approach,<sup>
<xref ref-type="bibr" rid="bibr18-0960327112456312">18</xref>
</sup> and evoked potentials.<sup>
<xref ref-type="bibr" rid="bibr19-0960327112456312">19</xref>,<xref ref-type="bibr" rid="bibr24-0960327112456312">24</xref>,<xref ref-type="bibr" rid="bibr25-0960327112456312">25</xref>
</sup> Spectral analysis of electroencephalogram was confirmed to increase the interobserver repeatability of the findings in comparison with visual assessment of the electroencephalogram. Although artificial neural networks showed promising results, spectral analysis of the electroencephalogram remains a reliable method for EEG analysis in HE.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112456312">18</xref>
</sup>
</p>
<p>Although behavioral manifestations of TAA intoxication were studied in previous investigations,<sup>
<xref ref-type="bibr" rid="bibr12-0960327112456312">12</xref>,<xref ref-type="bibr" rid="bibr17-0960327112456312">17</xref>
</sup> the effects of TAA on EEG activity were not extensively studied. We hypothesized that TAA may induce EEG abnormalities similar to human HE, thus confirming that this model may be suitable for further investigation of the pathogenesis of HE and possible therapeutical procedures in human HE. Based on this background, the aim of our study was to investigate the effects of TAA on EEG findings in rats, determined by spectral analysis.</p>
</sec>
<sec id="section2-0960327112456312" sec-type="materials|methods">
<title>Material and methods</title>
<sec id="section3-0960327112456312">
<title>Animals</title>
<p>Experiments were performed on adult male Wistar rats, weighting 170–200 g, that were raised on Military Medical Academy in Belgrade. Animals were kept in individual cages (55 × 35 × 30 cm) under standard laboratory conditions (ambient temperature 22 ± 1°C, relative humidity 50%, 12/12 h dark/light cycle with lights turned on at 9:00 a.m.) with free access to pelleted food and tap water. All experimental procedures were in full compliance with Directive of the European Parliament and of the Council (2010/63/EU) and approved by The Ethical Committee of the University of Belgrade (Permission No 298/5-2).</p>
<p>All animals were divided into following groups: (1) Control: saline-treated group (<italic>n</italic> = 8); (2) TAA-treated groups: TAA<sub>300</sub> (300 mg/kg; <italic>n</italic> = 8), TAA<sub>600</sub> (600 mg/kg; <italic>n</italic> = 10), and TAA<sub>900</sub> (900 mg/kg; <italic>n</italic> = 18). Daily dose of TAA (300 mg/kg) was administered intraperitoneally (i.p.) once (TAA<sub>300</sub>), twice (TAA<sub>600</sub>), or thrice (TAA<sub>900</sub>) in subsequent days. The total duration of the treatment was 1 (TAA<sub>300</sub>), 2 (TAA<sub>600</sub>), or 3 days (TAA<sub>900</sub>). Before administration, TAA was dissolved in saline in to a concentration of 100 mg/mL. EEG changes were followed a day after administration of the last dose of TAA (22.5–23.5 h).</p>
<p>Animals were killed 24 h after treatment, and blood and liver samples for pathohistologic analysis were collected. Liver was removed from rats immediately after killing, fixed in 4% buffered formalin, and embedded in paraffin. Sections of 5-µm-thick were stained with Masson’s trichrome staining protocol, and observed under light microscopy (Olympus BX41). Blood ammonia concentration, as a useful marker of liver failure, was determined by enzymatic test (BioMerieux Laboratory, France) in the samples collected from the right side of the heart.</p>
</sec>
<sec id="section4-0960327112456312">
<title>EEG studies</title>
<p>For EEG recordings, rats were anesthetized with ketamine (100 mg/kg i.p.) and three gold-plated electrodes were implanted over frontal, parietal, and occipital cortices by stereotaxic method. Treatment with TAA started 7 days after the implantation of electrodes in order to escape the interference between effects of surgery and TAA on EEG activity. An 8-channel EEG apparatus (RIZ, Zagreb, Croatia) was used. The signals were digitized using a SCB-68 data acquisition card (National Instruments Co., Austin, Texas, USA). A sampling frequency of 512 Hz/channel and 16-bit analogous to digital (A/D) conversion were used for the EEG signals. The cutoff frequencies for EEG recordings were set at 0.3 and 100 Hz for the high-pass and low-pass filters, respectively. Ambient noise was eliminated using a 50-Hz notch filter. Data acquisition and signal processing were performed with LabVIEW platform software developed in the Laboratory NeuroSciLaBG.<sup>
<xref ref-type="bibr" rid="bibr26-0960327112456312">26</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr27-0960327112456312">27</xref>
</sup> Electroencephalogram was analyzed every 30 min in the period 22.5–23.5 h after the administration of the last dose of TAA. This period was chosen, since our pilot study has shown that behavioral changes are most prominent about 24 h after TAA treatment (data not published). According to the modified method of Amodio et al.,<sup>
<xref ref-type="bibr" rid="bibr18-0960327112456312">18</xref>
</sup> for each time interval when electroencephalogram was analyzed, artifact-free recording was divided into eight epochs each lasting 12 s. The absolute and relative power spectral densities were calculated using the software for fast Fourier transformation method and the integrated energy signals were expressed as μV<sup>2</sup>/Hz. Upon completion of the recording sessions, the animal would be removed from the recording chamber and returned to its home cage.</p>
</sec>
<sec id="section5-0960327112456312">
<title>Statistical analysis</title>
<p>Blood ammonia concentration and absolute and relative power spectral densities were expressed as means ± SEM. Statistical significance of the difference in ammonia concentration was estimated by one-way analysis of variance (ANOVA), while significance of the difference in power spectral density was estimated by two-way ANOVA with Tuckey’s post hoc test. The value <italic>p</italic> &lt; 0.05 was considered statistically significant. For statistical analysis computer software Statistica 7.0 was used.</p>
</sec>
</sec>
<sec id="section6-0960327112456312">
<title>Results</title>
<p>All animals survived after TAA treatment in a dose of 300 mg/kg. Lethality of animals in TAA<sub>600</sub> group 24 h after treatment was 10% (1 of 10), while in TAA<sub>900</sub> group lethality was 44.4% (8 of 18). Blood ammonia concentration was significantly higher in all TAA-treated groups versus control group. Its concentration was also significantly higher in TAA<sub>600</sub> (81.5 ± 5.9 µmol/L) and TAA<sub>900</sub> groups (78.3 ± 6.5 µmol/L) in comparison with TAA<sub>300</sub> group (51.4 ± 4.7 µmol/L; <italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="fig1-0960327112456312">Figure 1</xref>).</p>
<fig id="fig1-0960327112456312" position="float">
<label>Figure 1.</label>
<caption>
<p>The effect of TAA on plasma ammonia concentration. Daily dose of TAA (300 mg/kg) was administered once (TAA<sub>300</sub>), twice (TAA<sub>600</sub>), or thrice (TAA<sub>900</sub>) in subsequent days. Blood samples for ammonia determination were collected from the right side of the heart 24 h after treatment. Significance of the difference in plasma ammonia concentration was estimated by one-way ANOVA with Fisher’s post hoc test (*<italic>p</italic> &lt; 0.05 and **<italic>p</italic> &lt; 0.01 vs. control, #<italic>p</italic> &lt; 0.01 vs. TAA<sub>300</sub> group). TAA: thioacetamide; ANOVA: analysis of variance</p>
</caption>
<graphic xlink:href="10.1177_0960327112456312-fig1.tif"/>
</fig>
<sec id="section7-0960327112456312">
<title>Histological analysis</title>
<p>Alterations in the hepatic tissue can be noticed 24 h after treatment in TAA<sub>300</sub> group. Acute hyperemia is followed by necrosis in the central vein area, which is confluent to form bridging (central-to-central) necrosis. Apoptotic hepatocytes can, also, be noticed. Portal areas are with normal, preserved structure (<xref ref-type="fig" rid="fig2-0960327112456312">Figure 2</xref>(b)). In TAA<sub>600</sub> group, liver sections revealed severe acute bridging necrosis 24 h after administration of the last dose of TAA. Apoptotic cells cannot be seen. Portal areas are still preserved (<xref ref-type="fig" rid="fig2-0960327112456312">Figure 2</xref>(c)). All sections of liver tissue in TAA<sub>900</sub> group showed severe bridging necrosis revealing inflammatory infiltrate and hemorrhage 24 h after the last administration of TAA (<xref ref-type="fig" rid="fig2-0960327112456312">Figure 2</xref>(d)).</p>
<fig id="fig2-0960327112456312" position="float">
<label>Figure 2.</label>
<caption>
<p>Histopathological changes in the liver after intraperitoneal TAA administration on sections stained with Masson’s trichrome staining. (a) Liver section from control, saline-treated group with preserved structure of parenchyma. (b) Liver section from TAA<sub>300</sub> group 24 h after TAA administration with acute bridging necrosis, prominent cells with karyorrhexis, karyolysis, or in apoptosis, and preservation of periportal zone. (c) Liver section from TAA<sub>600</sub> group 24 h after second TAA administration with bridging necrosis and preservation of periportal zone. (d) Liver section from TAA<sub>900</sub> group 24 h after third TAA administration with bridging necrosis and preservation of periportal zone. Masson’s trichrome staining. p: portal area; TAA: thioacetamide.</p>
</caption>
<graphic xlink:href="10.1177_0960327112456312-fig2.tif"/>
</fig>
</sec>
<sec id="section8-0960327112456312">
<title>EEG findings</title>
<p>Results of our study showed that absolute beta power spectral density was significantly higher in TAA<sub>300</sub> versus control group at all time intervals. The most pronounced increase was evident 23.5 h after treatment. While absolute beta power was significantly higher in TAA<sub>600</sub> group in comparison with control group only 23 h (<italic>p</italic> &lt; 0.05) and 23.5 h (<italic>p</italic> &lt; 0.01) after the administration of the last dose, no significant change in absolute beta power was evident in TAA<sub>900</sub> group at all time intervals (<xref ref-type="table" rid="table1-0960327112456312">Table 1</xref>). In contrast to absolute beta power, relative beta power spectral density was significantly lower in TAA<sub>300</sub> group in comparison with control group at all time intervals (<italic>p</italic> &lt; 0.01). No significant changes in this parameter were evident in TAA<sub>600</sub> and TAA<sub>900</sub> groups versus control (<xref ref-type="table" rid="table1-0960327112456312">Table 1</xref>).</p>
<table-wrap id="table1-0960327112456312" position="float">
<label>Table 1.</label>
<caption>
<p>The effect of TAA on absolute and relative power in the beta band<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table1-0960327112456312" xlink:href="10.1177_0960327112456312-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Time after treatment (h)</th>
<th colspan="4">Absolute power density in beta band (μV<sup>2</sup>/Hz)</th>
<th colspan="4">Relative power density in beta band (%)</th>
</tr>
<tr>
<th>Control</th>
<th>TAA<sub>300</sub>
</th>
<th>TAA<sub>600</sub>
</th>
<th>TAA<sub>900</sub>
</th>
<th>Control</th>
<th>TAA<sub>300</sub>
</th>
<th>TAA<sub>600</sub>
</th>
<th>TAA<sub>900</sub>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>22.5</td>
<td>23.32 ± 6.01</td>
<td>39.81 ± 10.17<sup>b</sup>
</td>
<td>26.16 ± 7.09</td>
<td>19.87 ± 2.65</td>
<td>8.4 ± 1.7</td>
<td>5.4 ± 1.1<sup>b</sup>
</td>
<td>7.3 ± 0.2</td>
<td>8.9 ± 0.3</td>
</tr>
<tr>
<td>23.0</td>
<td>23.65 ± 6.03</td>
<td>37.15 ± 9.52<sup>c</sup>
</td>
<td>38.55 ± 11.32<sup>c</sup>
</td>
<td>24.12 ± 4.45</td>
<td>8.6 ± 1.6</td>
<td>4.4 ± 1.1<sup>b</sup>
</td>
<td>7.9 ± 1.2</td>
<td>8.5 ± 0.1</td>
</tr>
<tr>
<td>23.5</td>
<td>23.38 ± 5.99</td>
<td>68.14 ± 17.03<sup>b</sup>
</td>
<td>61.34 ± 13.87<sup>b</sup>
</td>
<td>20.38 ± 3.41</td>
<td>9.1 ± 0.9</td>
<td>3.7 ± 0.4<sup>b</sup>
</td>
<td>8.2 ± 1.9</td>
<td>9.4 ± 0.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327112456312">
<p>TAA: thioacetamide; EEG: electroencephalographic; ANOVA: analysis of variance.</p>
</fn>
<fn id="table-fn2-0960327112456312">
<p>
<sup>a</sup>Daily dose of TAA (300 mg/kg) was administered once (TAA<sub>300</sub>), twice (TAA<sub>600</sub>), or thrice (TAA<sub>900</sub>) in subsequent days. EEG was recorded 22.5–23.5 h after the administration of the last dose of TAA. The absolute and relative power spectral densitieswere calculated using the software for fast Fourier transformation method. Significance of the difference in power spectral density was estimated by two-way ANOVA with Tuckey’s post hoc test.</p>
</fn>
<fn id="table-fn3-0960327112456312">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.01 versus control.</p>
</fn>
<fn id="table-fn4-0960327112456312">
<p>
<sup>c</sup>
<italic>p</italic> &lt; 0.05 versus control.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>When compared with control, the absolute alpha power spectral density was significantly changed in the following manner: higher in TAA<sub>300</sub> and lower in TAA<sub>900</sub> group at all time intervals (<italic>p</italic> &lt; 0.01) and higher in TAA<sub>600</sub> only 23.5 h after treatment (277.5 ± 59.9 μV<sup>2</sup>/Hz vs. 79.9 ± 22.8 μV<sup>2</sup>/Hz; <italic>p</italic> &lt; 0.01; <xref ref-type="table" rid="table2-0960327112456312">Table 2</xref>). The relative alpha power spectral density was significantly higher in TAA<sub>300</sub> versus control group at all time intervals and in TAA<sub>600</sub> versus control 23.5 h after treatment. On the other hand, in TAA<sub>900</sub> group, no significant change in relative alpha power was evident when compared with control group (<xref ref-type="table" rid="table2-0960327112456312">Table 2</xref>).</p>
<table-wrap id="table2-0960327112456312" position="float">
<label>Table 2.</label>
<caption>
<p>The effect of TAA on absolute and relative power in the alpha band<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table2-0960327112456312" xlink:href="10.1177_0960327112456312-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Time after treatment (h)</th>
<th colspan="4">Absolute power density in alpha band (μV<sup>2</sup>/Hz)</th>
<th colspan="4">Relative power density in alpha band (%)</th>
</tr>
<tr>
<th>Control</th>
<th>TAA<sub>300</sub>
</th>
<th>TAA<sub>600</sub>
</th>
<th>TAA<sub>900</sub>
</th>
<th>Control</th>
<th>TAA<sub>300</sub>
</th>
<th>TAA<sub>600</sub>
</th>
<th>TAA<sub>900</sub>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>22.5</td>
<td>80.76 ± 25.46</td>
<td>161.05 ± 46.73<sup>b</sup>
</td>
<td>82.50 ± 24.67</td>
<td>17.32 ± 3.46<sup>b</sup>
</td>
<td>11.9 ± 1.0</td>
<td>22.0 ± 2.9<sup>b</sup>
</td>
<td>14.9 ± 2.7</td>
<td>9.7 ± 0.5</td>
</tr>
<tr>
<td>23.0</td>
<td>85.19 ± 26.63</td>
<td>185.02 ± 26.94<sup>b</sup>
</td>
<td>131.21 ± 43.86</td>
<td>24.07 ± 4.13<sup>b</sup>
</td>
<td>9.5 ± 0.6</td>
<td>23.9 ± 2.6<sup>b</sup>
</td>
<td>9.9 ± 1.8</td>
<td>9.2 ± 0.8</td>
</tr>
<tr>
<td>23.5</td>
<td>79.90 ± 22.83</td>
<td>270.73 ± 42.21<sup>b</sup>
</td>
<td>277.54 ± 59.98<sup>b</sup>
</td>
<td>22.75 ± 3.49<sup>b</sup>
</td>
<td>10.6 ± 2.4</td>
<td>14.6 ± 2.0<sup>c</sup>
</td>
<td>14.5 ± 1.9<sup>c</sup>
</td>
<td>10.9 ± 1.9</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0960327112456312">
<p>TAA: thioacetamide; ANOVA: analysis of variance.</p>
</fn>
<fn id="table-fn6-0960327112456312">
<p>
<sup>a</sup>Significance of the difference in power spectral density was estimated by two-way ANOVA with Tuckey’s post hoc test (for further information see <xref ref-type="table" rid="table1-0960327112456312">Table 1</xref>).</p>
</fn>
<fn id="table-fn7-0960327112456312">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.01 versus control.</p>
</fn>
<fn id="table-fn8-0960327112456312">
<p>
<sup>c</sup>
<italic>p</italic> &lt; 0.05 versus control.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Spectral analysis revealed that the absolute theta power spectral density was significantly higher in TAA<sub>300</sub> and TAA<sub>600</sub> groups versus control 23.5 h after treatment (<italic>p</italic> &lt; 0.01). In TAA<sub>900</sub> group, absolute theta power was significantly lower at all time intervals in comparison with control group (<italic>p</italic> &lt; 0.01; <xref ref-type="table" rid="table3-0960327112456312">Table 3</xref>). We observed that the relative theta power spectral density in experimental groups in comparison with control group showed: no change in TAA<sub>300</sub>, a significant increase in TAA<sub>600</sub>, 22.5 h after treatment (<italic>p</italic> &lt; 0.01), and a significant decrease in TAA<sub>900</sub> group (<italic>p</italic> &lt; 0.01; <xref ref-type="table" rid="table3-0960327112456312">Table 3</xref>)<sub>.</sub>
</p>
<table-wrap id="table3-0960327112456312" position="float">
<label>Table 3.</label>
<caption>
<p>The effect of TAA on absolute and relative power in the theta band<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table3-0960327112456312" xlink:href="10.1177_0960327112456312-table3.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Time after treatment (h)</th>
<th colspan="4">Absolute power density in theta band (μV<sup>2</sup>/Hz)</th>
<th colspan="4">Relative power density in theta band (%)</th>
</tr>
<tr>
<th>Control</th>
<th>TAA<sub>300</sub>
</th>
<th>TAA<sub>600</sub>
</th>
<th>TAA<sub>900</sub>
</th>
<th>Control</th>
<th>TAA<sub>300</sub>
</th>
<th>TAA<sub>600</sub>
</th>
<th>TAA<sub>900</sub>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>22.5</td>
<td>124.22 ± 34.39</td>
<td>138.73 ± 20.75</td>
<td>95.32 ± 11.49</td>
<td>28.17 ± 7.11<sup>b</sup>
</td>
<td>18.3 ± 0.8</td>
<td>18.9 ± 1.3</td>
<td>26.5 ± 1.9<sup>b</sup>
</td>
<td>7.1 ± 0.2<sup>b</sup>
</td>
</tr>
<tr>
<td>23.0</td>
<td>134.39 ± 41.24</td>
<td>93.60 ± 28.10</td>
<td>184.66 ± 85.80</td>
<td>30.32 ± 6.24<sup>b</sup>
</td>
<td>15.0 ± 2.1</td>
<td>18.3 ± 1.9</td>
<td>16.2 ± 2.8</td>
<td>5.8 ± 1.2<sup>b</sup>
</td>
</tr>
<tr>
<td>23.5</td>
<td>140.81 ± 37.46</td>
<td>308.37 ± 25.17<sup>b</sup>
</td>
<td>363.71 ± 34.03<sup>b</sup>
</td>
<td>29.86 ± 6.99<sup>b</sup>
</td>
<td>18.7 ± 2.0</td>
<td>16.6 ± 1.9</td>
<td>19.1 ± 2.6</td>
<td>6.1 ± 1.0<sup>b</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0960327112456312">
<p>TAA: thioacetamide; ANOVA: analysis of variance.</p>
</fn>
<fn id="table-fn10-0960327112456312">
<p>
<sup>a</sup>Significance of the difference in power spectral density was estimated by two-way ANOVA with Tuckey’s post hoc test (for further information see <xref ref-type="table" rid="table1-0960327112456312">Table 1</xref>).</p>
</fn>
<fn id="table-fn11-0960327112456312">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.01 versus control.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>While no significant difference in the absolute delta power spectral density was evident between TAA<sub>300</sub> and control group (<italic>p</italic> &gt; 0.05), absolute delta power was significantly higher in TAA<sub>600</sub> group versus control group at all time intervals. In contrast, a significant fall in absolute delta power was evident in TAA<sub>900</sub> group in comparison with control group at the same time (<italic>p</italic> &lt; 0.01; <xref ref-type="table" rid="table4-0960327112456312">Table 4</xref>). The relative delta power spectral density was significantly lower in TAA<sub>300</sub> and TAA<sub>600</sub> groups versus control 22.5 h after treatment (<italic>p</italic> &lt; 0.01). This decrease remains evident in TAA<sub>300</sub> group 23 and 23.5 h after TAA administration. At the same time, relative delta power was not significantly different in TAA<sub>600</sub> group versus control (<italic>p</italic> &gt; 0.05). In contrast to TAA<sub>300</sub> and TAA<sub>600</sub> groups, relative delta power was significantly higher in TAA<sub>900</sub> group in comparison with control group at all time intervals (<italic>p</italic> &lt; 0.01; <xref ref-type="table" rid="table4-0960327112456312">Table 4</xref>).</p>
<table-wrap id="table4-0960327112456312" position="float">
<label>Table 4.</label>
<caption>
<p>The effect of TAA on absolute and relative power in the delta band<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table4-0960327112456312" xlink:href="10.1177_0960327112456312-table4.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Time after treatment (h)</th>
<th colspan="4">Absolute power density in delta band (μV<sup>2</sup>/Hz)</th>
<th colspan="4">Relative power density in delta band (%)</th>
</tr>
<tr>
<th>Control</th>
<th>TAA<sub>300</sub>
</th>
<th>TAA<sub>600</sub>
</th>
<th>TAA<sub>900</sub>
</th>
<th>Control</th>
<th>TAA<sub>300</sub>
</th>
<th>TAA<sub>600</sub>
</th>
<th>TAA<sub>900</sub>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>22.5</td>
<td>447.34 ± 76.23</td>
<td>391.61 ± 124.86</td>
<td>855.91 ± 156.10<sup>b</sup>
</td>
<td>173.97 ± 44.61<sup>b</sup>
</td>
<td>66.2 ± 0.6</td>
<td>53.5 ± 1.9<sup>b</sup>
</td>
<td>50.3 ± 1.9<sup>b</sup>
</td>
<td>78.5 ± 0.2<sup>b</sup>
</td>
</tr>
<tr>
<td>23.0</td>
<td>650.99 ± 195.64</td>
<td>415.81 ± 67.14</td>
<td>942.18 ± 223.49<sup>b</sup>
</td>
<td>193.08 ± 50.75<sup>b</sup>
</td>
<td>72.8 ± 0.7</td>
<td>39.3 ± 0.2<sup>b</sup>
</td>
<td>71.0 ± 2.6</td>
<td>79.9 ± 1.5<sup>b</sup>
</td>
</tr>
<tr>
<td>23.5</td>
<td>507.66 ± 133.86</td>
<td>409.34 ± 159.76</td>
<td>1205.02 ± 210.93<sup>b</sup>
</td>
<td>184.17 ± 49.06<sup>b</sup>
</td>
<td>67.5 ± 0.9</td>
<td>55.1 ± 2.6<sup>b</sup>
</td>
<td>65.1 ± 0.6</td>
<td>77.8 ± 0.5<sup>b</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn12-0960327112456312">
<p>TAA: thioacetamide; ANOVA: analysis of variance.</p>
</fn>
<fn id="table-fn13-0960327112456312">
<p>
<sup>a</sup>Significance of the difference in power spectral density was estimated by two-way ANOVA with Tuckey’s post hoc test (for further information see <xref ref-type="table" rid="table1-0960327112456312">Table 1</xref>).</p>
</fn>
<fn id="table-fn14-0960327112456312">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.01 versus control.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section9-0960327112456312">
<title>Discussion</title>
<p>According to blood ammonia concentration, TAA induced liver failure irrespective of its dose (<xref ref-type="fig" rid="fig1-0960327112456312">Figure 1</xref>). Histological analysis of the liver confirms hepatotoxic effects of TAA (<xref ref-type="fig" rid="fig2-0960327112456312">Figure 2</xref>), thus indicating that liver injury may be, at least partly, responsible for TAA-induced EEG changes found in our study. Direct neurotoxic effects of TAA were also postulated: cytochrome P450-dependent monooxygenase, an enzyme involved in TAA metabolism in the liver, is present in the brain. This enzyme is suggested to be involved in the production of toxic metabolites (e.g. thioacetamide-<italic>S</italic>-<italic>S</italic> oxide).<sup>
<xref ref-type="bibr" rid="bibr28-0960327112456312">28</xref>
<xref ref-type="bibr" rid="bibr29-0960327112456312"/>–<xref ref-type="bibr" rid="bibr30-0960327112456312">30</xref>
</sup> The formation of these metabolites were confirmed in the rat brain after intraperitoneal TAA administration,<sup>
<xref ref-type="bibr" rid="bibr31-0960327112456312">31</xref>
</sup> but was insignificant after the ingestion of TAA in the drinking water.<sup>
<xref ref-type="bibr" rid="bibr32-0960327112456312">32</xref>
</sup> Since TAA ingestion in the water induced neurological changes, it may be suggested that liver failure contributes to the majority of neurotoxic effects seen in TAA intoxication.<sup>
<xref ref-type="bibr" rid="bibr32-0960327112456312">32</xref>
</sup>
</p>
<p>In previous studies, different classification scales were used to describe EEG alterations in HE. One of the earliest classifications was according to the qualitative visual assessment of electroencephalograph.<sup>
<xref ref-type="bibr" rid="bibr20-0960327112456312">20</xref>
</sup> Based on this classification, the patients with alpha rhythm disturbed by random theta waves over both hemispheres or with diffuse background activity in the theta range with random appearance of high waves in the delta range were at increased risk of death at 1-year period. The worst prognosis corresponded to the severe disorganization of EEG activity with diffuse asynchronous theta and delta rhythm.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112456312">18</xref>
</sup> Our results are in accordance with these findings, since the highest mortality in our study was associated with a relative increase in delta band in TAA<sub>900</sub> group (<xref ref-type="table" rid="table4-0960327112456312">Table 4</xref>). However, this classification scale carries a risk of subjective interpretation with subsequent low interobserver repeatability.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112456312">18</xref>
</sup>
</p>
<p>In order to improve the repeatability of the method, spectral analysis-based classification was introduced by Van der Rijt et al.<sup>
<xref ref-type="bibr" rid="bibr23-0960327112456312">23</xref>
</sup> Apart from repeatability, spectral analysis was shown to provide indexes that correlate with both clinical findings and prognosis of HE.<sup>
<xref ref-type="bibr" rid="bibr33-0960327112456312">33</xref>
</sup> This scale classifies EEG manifestations, according to the mean dominant frequency and relative power in theta and delta bands. The highest grade (the most severe HE) according to this classification corresponds to mean dominant frequency ≤7.3 Hz and delta relative power ≥45%.<sup>
<xref ref-type="bibr" rid="bibr21-0960327112456312">21</xref>
<xref ref-type="bibr" rid="bibr22-0960327112456312"/>–<xref ref-type="bibr" rid="bibr23-0960327112456312">23</xref>
</sup> According to Van der Rijt et al., although classification of EEG changes may be useful in human population,<sup>
<xref ref-type="bibr" rid="bibr18-0960327112456312">18</xref>
</sup> it cannot be used for the evaluation of TAA-induced EEG changes in rats, since all TAA-treated groups in our study had delta relative power ≥45%.</p>
<p>However, spectral analysis remains a reliable method for EEG analysis in TAA-induced encephalopathy, since our study has shown that TAA induces EEG changes in a dose-dependent manner. EEG findings in TAA<sub>300</sub> group (<xref ref-type="table" rid="table1-0960327112456312">Tables 1</xref> and <xref ref-type="table" rid="table2-0960327112456312">2</xref>) have shown a correlation with EEG manifestations of mild HE in humans, which is associated with initial increase in EEG wave voltage.<sup>
<xref ref-type="bibr" rid="bibr19-0960327112456312">19</xref>
</sup> However, other studies showed controversial results related to the initial changes in relative representation of various EEG waves in human HE. Some studies found a frontal predominance of the alpha rhythm,<sup>
<xref ref-type="bibr" rid="bibr34-0960327112456312">34</xref>,<xref ref-type="bibr" rid="bibr35-0960327112456312">35</xref>
</sup> while others, similar to the present study, described an increase in beta waves in mild HE.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112456312">18</xref>,<xref ref-type="bibr" rid="bibr36-0960327112456312">36</xref>
</sup> On the other hand, low-power beta activity was also described in the initial stages of HE in humans.<sup>
<xref ref-type="bibr" rid="bibr36-0960327112456312">36</xref>
</sup> These initial EEG changes may be explained by increased GABAergic and glutamatergic activities,<sup>
<xref ref-type="bibr" rid="bibr19-0960327112456312">19</xref>
</sup> which are increased in acute HE.<sup>
<xref ref-type="bibr" rid="bibr13-0960327112456312">13</xref>,<xref ref-type="bibr" rid="bibr37-0960327112456312">37</xref>
</sup>
</p>
<p>In contrast to 300 mg/kg, TAA in a dose of 600 mg/kg induced an increase in the delta wave voltage as the earliest EEG change in the developed encephalopathy. An increase in beta, alpha, and theta voltage were evident only 23.5 h after treatment (<xref ref-type="table" rid="table1-0960327112456312">Tables 1</xref> to <xref ref-type="table" rid="table3-0960327112456312">3</xref> and <xref ref-type="fig" rid="fig3-0960327112456312">Figure 3</xref>). An increase in voltage of delta waves was associated with comatose state and lethality (10%) in this group. Although relative representations of delta and theta waves were significantly changed 22.5 h after treatment (<xref ref-type="table" rid="table3-0960327112456312">Tables 3</xref> and <xref ref-type="table" rid="table4-0960327112456312">4</xref>), these parameters have no prognostic value, since later these changes were inconsistent, although coma was clearly evident. Based on the present study, the first sign of moderate to severe TAA-induced encephalopathy is increase in voltage of delta waves and not the relative representation of EEG waves.</p>
<fig id="fig3-0960327112456312" position="float">
<label>Figure 3.</label>
<caption>
<p>Representative EEG tracings in TAA<sub>300</sub> (a), TAA<sub>600</sub> (b), and TAA<sub>900</sub> groups (c). Daily dose of TAA (300 mg/kg) was administered once (TAA<sub>300</sub>), twice (TAA<sub>600</sub>), or thrice (TAA<sub>900</sub>) in subsequent days. EEG was recorded 22.5–23.5 h after the administration of the last dose of TAA. TAA: thioacetamide; EEG: electroencephalograph.</p>
</caption>
<graphic xlink:href="10.1177_0960327112456312-fig3.tif"/>
</fig>
<p>Models of HE, induced by high doses of galactosamine and by ligation of hepatic artery after previous portocaval shunt in rats, have shown an increase in low-frequency EEG activity.<sup>
<xref ref-type="bibr" rid="bibr38-0960327112456312">38</xref>
</sup> TAA in a dose of 900 mg/kg induced similar changes in our study (<xref ref-type="table" rid="table2-0960327112456312">Tables 2</xref> to <xref ref-type="table" rid="table4-0960327112456312">4</xref>) and they correspond to the EEG changes in severe HE in humans.<sup>
<xref ref-type="bibr" rid="bibr19-0960327112456312">19</xref>
</sup> Hepatic coma is associated with various EEG abnormalities, from alpha rhythm admixed with theta slowing in early stages to theta–delta slowing over both hemispheres in late phases of coma. Triphasic waves may be present, but are not always evident.<sup>
<xref ref-type="bibr" rid="bibr39-0960327112456312">39</xref>
</sup> Late stage of coma is associated with flattening of the electroencephalogram followed by a predominance of delta waves.<sup>
<xref ref-type="bibr" rid="bibr40-0960327112456312">40</xref>
</sup> Similar findings were obtained from studies of fulminant liver failure performed in hepatectomized swines.<sup>
<xref ref-type="bibr" rid="bibr41-0960327112456312">41</xref>
</sup> Findings of our study indicate that TAA in a dose of 900 mg/kg provokes EEG manifestations of deep coma, which are further followed by high mortality (44.4%).</p>
<p>Quantitative EEG analysis has shown an increase in relative theta power in the posterior derivations in 15–30% of cirrhotic patients.<sup>
<xref ref-type="bibr" rid="bibr33-0960327112456312">33</xref>
</sup> Our findings (<xref ref-type="table" rid="table3-0960327112456312">Table 3</xref>) do not precisely correlate with findings in human studies, probably because TAA induced acute liver failure and not cirrhosis in our study and because of possible additional toxic effects of TAA on the brain irrespective of liver injury-induced encephalopathy.</p>
<p>Apart from dose dependency of EEG changes in TAA-induced encephalopathy, another confirmation of reliability of spectral EEG analysis in this type of encephalopathy is the prognostic value of this method. Based on EEG manifestations and mortality found in the present study, it can be suggested that an increase in relative power of the delta band with simultaneous decrease in the theta band (<xref ref-type="table" rid="table3-0960327112456312">Tables 3</xref> and <xref ref-type="table" rid="table4-0960327112456312">4</xref>), along with a decline in EEG voltage may be a bad prognostic sign in TAA-induced encephalopathy.</p>
<p>The usefulness of the study is to define model of TAA-induced HE in a more precise manner by electroencephalography. Based on these results, it can be concluded that TAA in a dose of 300 mg/kg induces EEG manifestations that correlate with mild HE in humans. The first sign of increased severity of TAA-induced encephalopathy is an increase in voltage in the delta band, which is evident in TAA<sub>600</sub> group. However, a dose of 900 mg/kg TAA induced an encephalopathy that correlates with severe HE in humans, associated with the worst prognosis. Severe TAA-induced encephalopathy, accompanied by coma and relatively high mortality, was associated with an increase in delta band and a decrease in theta band representation together with a decrease in EEG voltage.</p>
<p>According to EEG manifestations, TAA in a dose of 900 mg/kg may be used as a suitable model for the investigation of pathogenetic mechanisms and possible therapeutical procedures in severe stages of HE.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0960327112456312">
<label>Conflict of interest</label>
<p>The authors declared no conflicts of interest.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0960327112456312">
<label>Funding</label>
<p>This work was supported by the Ministry of Education and Science of Serbia, grant no. 175032.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327112456312">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gammal</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>EA</given-names>
</name>
</person-group>. <article-title>Hepatic encephalopathy</article-title>. <source>Med Clin N Am</source> <year>1989</year>; <volume>73</volume>: <fpage>793</fpage>–<lpage>813</lpage>.</citation>
</ref>
<ref id="bibr2-0960327112456312">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albrecht</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zielińska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Norenberg</surname>
<given-names>MD</given-names>
</name>
</person-group>. <article-title>Glutamine as a mediator of ammonia neurotoxicity: a critical appraisal</article-title>. <source>Biochem Pharmacol</source> <year>2010</year>; <volume>80</volume>: <fpage>1303</fpage>–<lpage>1308</lpage>.</citation>
</ref>
<ref id="bibr3-0960327112456312">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norenberg</surname>
<given-names>MD</given-names>
</name>
</person-group>. <article-title>The role of astrocytes in hepatic encephalopathy</article-title>. <source>Neurochem Pathol</source> <year>1987</year>; <volume>6</volume>: <fpage>13</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr4-0960327112456312">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rama-Rao</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Jayakumar</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Norenberg</surname>
<given-names>MD</given-names>
</name>
</person-group>. <article-title>Ammonia neurotoxicity: role of the mitochondrial permeability transition</article-title>. <source>Metab Brain Dis</source> <year>2003</year>; <volume>18</volume>: <fpage>113</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr5-0960327112456312">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norenberg</surname>
<given-names>MD</given-names>
</name>
</person-group>. <article-title>Alight and electron microscopic study of experimental portal-systemic (ammonia) encephalopathy. Progression and reversal of the disorder</article-title>. <source>Lab Invest</source> <year>1977</year>; <volume>36</volume>: <fpage>618</fpage>–<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr6-0960327112456312">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jalan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shawcross</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>The molecular pathogenesis of hepatic encephalopathy</article-title>. <source>Int J Biochem Cell Biol</source> <year>2003</year>; <volume>35</volume>: <fpage>1175</fpage>–<lpage>1181</lpage>.</citation>
</ref>
<ref id="bibr7-0960327112456312">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarros</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Theocharis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Skandali</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tsakiris</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Effects of fulminant hepatic encephalopathy on the adult rat brain antioxidant status and the activities of acetylcholinesterase, (Na(+), K(+))- and Mg(2+)-ATPase: comparison of the enzymes’ response to in vitro treatment with ammonia</article-title>. <source>Metab Brain Dis</source> <year>2008</year>; <volume>23</volume>: <fpage>255</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr8-0960327112456312">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butterworth</surname>
<given-names>RF</given-names>
</name>
</person-group>. <article-title>Neuroinflammation in acute liver failure: mechanisms and novel therapeutic targets</article-title>. <source>Neurochem Int</source> <year>2011</year>; <volume>59</volume>: <fpage>830</fpage>–<lpage>836</lpage>.</citation>
</ref>
<ref id="bibr9-0960327112456312">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cauli</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rodrigo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Llansola</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Montoliu</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Glutamatergic and GABAergic neurotransmission and neuronal circuits in hepatic encephalopathy</article-title>. <source>Metab Brain Dis</source> <year>2009</year>; <volume>24</volume>: <fpage>69</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr10-0960327112456312">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahboucha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Butterworth</surname>
<given-names>RF</given-names>
</name>
</person-group>. <article-title>The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy</article-title>. <source>Neurochem Int</source> <year>2008</year>; <volume>52</volume>: <fpage>575</fpage>–<lpage>587</lpage>.</citation>
</ref>
<ref id="bibr11-0960327112456312">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shawcross</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jalan</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation</article-title>. <source>Cell Mol Life Sci</source> <year>2005</year>; <volume>62</volume>: <fpage>2295</fpage>–<lpage>2304</lpage>.</citation>
</ref>
<ref id="bibr12-0960327112456312">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norton</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>McConnell</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Rodriguez-Sierra</surname>
<given-names>JF</given-names>
</name>
</person-group>. <article-title>Behavioral and physiological sex differences observed in an animal model of fulminant hepatic encephalopathy in the rat</article-title>. <source>Physiol Behav</source> <year>1997</year>; <volume>62</volume>: <fpage>1113</fpage>–<lpage>1124</lpage>.</citation>
</ref>
<ref id="bibr13-0960327112456312">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miranda</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>CX</given-names>
</name>
<etal/>
</person-group>. <article-title>A thioacetamide-induced hepatic encephalopathy model in C57BL/6 mice</article-title>. <source>Arq Neuropsiquiatr</source> <year>2010</year>; <volume>68</volume>: <fpage>597</fpage>–<lpage>602</lpage>.</citation>
</ref>
<ref id="bibr14-0960327112456312">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paik</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>MK</given-names>
</name>
<etal/>
</person-group>. <article-title>Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats</article-title>. <source>Exp Mol Med</source> <year>2011</year>; <volume>43</volume>: <fpage>341</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr15-0960327112456312">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hilgier</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Benveniste</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Diemer</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Decreased glucose utilization in discrete brain regions of rat in thioacetamide-induced hepatic encephalopathy as measured with [<sup>3</sup>H]-deoxyglucose</article-title>. <source>Acta Neurol Scand</source> <year>1991</year>; <volume>83</volume>: <fpage>353</fpage>–<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr16-0960327112456312">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uehara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hirode</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kiyosawa</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>A toxicogenomics approach for early assessment of potential non-genotoxic hepatocarcinogenicity of chemicals in rats</article-title>. <source>Toxicology</source> <year>2008</year>; <volume>250</volume>: <fpage>15</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr17-0960327112456312">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terblanche</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hickman</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Animal models of fulminant hepatic failure</article-title>. <source>Dig Dis Sci</source> <year>1991</year>; <volume>36</volume>: <fpage>770</fpage>–<lpage>774</lpage>.</citation>
</ref>
<ref id="bibr18-0960327112456312">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amodio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pellegrini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ubiali</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mathy</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>The EEG assessment of low-grade hepatic encephalopathy: Comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis</article-title>. <source>Clin Neurophysiol</source> <year>2006</year>; <volume>117</volume>: <fpage>2243</fpage>–<lpage>2251</lpage>.</citation>
</ref>
<ref id="bibr19-0960327112456312">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerit</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Amantini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>PW</given-names>
</name>
<etal/>
</person-group>. <article-title>Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines</article-title>. <source>Liver Int</source> <year>2009</year>; <volume>29</volume>: <fpage>789</fpage>–<lpage>796</lpage>.</citation>
</ref>
<ref id="bibr20-0960327112456312">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parsons-Smith</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Summerskill</surname>
<given-names>WHJ</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Sherlock</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>The electroencephalograph in liver disease</article-title>. <source>Lancet</source> <year>1957</year>; <volume>2</volume>: <fpage>867</fpage>–<lpage>871</lpage>.</citation>
</ref>
<ref id="bibr21-0960327112456312">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amodio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Del Piccolo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Marchetti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Angeli</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests</article-title>. <source>Hepatology</source> <year>1999</year>; <volume>29</volume>: <fpage>1662</fpage>–<lpage>1667</lpage>.</citation>
</ref>
<ref id="bibr22-0960327112456312">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amodio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Marchetti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Del Piccolo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>de Tourtchaninoff</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Spectral versus visual EEG analysis in mild hepatic encephalopathy</article-title>. <source>Clin Neurophysiol</source> <year>1999</year>; <volume>110</volume>: <fpage>1334</fpage>–<lpage>1344</lpage>.</citation>
</ref>
<ref id="bibr23-0960327112456312">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van der Rijt</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Schalm</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>De Groot</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>De Vlieger</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Objective measurement of hepatic encephalopathy by means of automated EEG analysis</article-title>. <source>Electroencephalogr Clin Neurophysiol</source> <year>1984</year>; <volume>57</volume>: <fpage>423</fpage>–<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr24-0960327112456312">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehndiratta</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Sood</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Sarin</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Comparative evaluation of visual, somatosensory, and auditory evoked potentials in the detection of subclinical hepatic encephalopathy in patients with nonalcoholic cirrhosis</article-title>. <source>Am J Gastroenterol</source> <year>1990</year>; <volume>85</volume>: <fpage>799</fpage>–<lpage>803</lpage>.</citation>
</ref>
<ref id="bibr25-0960327112456312">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Utku</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Asil</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Balci</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Uzunca</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Hepatic myelopathy with spastic paraparesis</article-title>. <source>Clin Neurol Neurosurg</source> <year>2005</year>; <volume>107</volume>: <fpage>514</fpage>–<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr26-0960327112456312">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hrnčić</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rašić-Marković</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krstić</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Macut</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>The role of nitric oxide in homocysteine thiolactone-induced seizures in adult rats</article-title>. <source>Cell Mol Neurobiol</source> <year>2010</year>; <volume>30</volume>: <fpage>219</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr27-0960327112456312">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stanojlović</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rašić-Marković</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hrnčić</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Šušić</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Two types of seizures in homocysteine thiolactone-treated adult rats, behavioral and electroencephalographic study</article-title>. <source>Cell Mol Neurobiol</source> <year>2009</year>; <volume>29</volume>: <fpage>329</fpage>–<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr28-0960327112456312">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawant</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Dnyanmote</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Warbritton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Latendresse</surname>
<given-names>JR</given-names>
</name>
<etal/>
</person-group>. <article-title>Type 2 diabetic rats are sensitive to thioacetamide hepatotoxicity</article-title>. <source>Toxicol Appl Pharmacol</source> <year>2006</year>; <volume>211</volume>: <fpage>221</fpage>–<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr29-0960327112456312">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shankar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bucci</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Warbritton</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Diallyl sulfide inhibition of CYP2E1 does not rescue diabetic rats from thioacetamide-induced mortality</article-title>. <source>Toxicol Appl Pharmacol</source> <year>2001</year>; <volume>173</volume>: <fpage>27</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr30-0960327112456312">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>YQ</given-names>
</name>
</person-group>. <article-title>Determination of brain cytochrome P450 2E1 activity in rat with the probe of chlorzoxazone by liquid chromatography-mass spectrometry</article-title>. <source>J Chromatogr B: Anal Technol Biomed Life Sci</source> <year>2011</year>; <volume>879</volume>: <fpage>260</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr31-0960327112456312">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peeling</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shoemaker</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gauthier</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Benarroch</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Cerebral metabolic and histological effects of thioacetamide-induced liver failure</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source> <year>1993</year>; <volume>265</volume>: <fpage>572</fpage>–<lpage>578</lpage>.</citation>
</ref>
<ref id="bibr32-0960327112456312">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Méndez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mendez-Lopez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Aller</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Mammillary body alterations and spatial memory impairment in Wistar rats with thioacetamide-induced cirrhosis</article-title>. <source>Brain Res</source> <year>2008</year>; <volume>1233</volume>: <fpage>185</fpage>–<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr33-0960327112456312">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amodio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Del Piccolo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Petteno</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mapelli</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients</article-title>. <source>J Hepatol</source> <year>2001</year>; <volume>35</volume>: <fpage>37</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr34-0960327112456312">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montagnese</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>MY</given-names>
</name>
</person-group>. <article-title>Spatio-temporal decomposition of the electroencephalogram in patients with cirrhosis</article-title>. <source>J Hepatol</source> <year>2007</year>; <volume>46</volume>: <fpage>447</fpage>–<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr35-0960327112456312">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sagales</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gimeno</surname>
<given-names>V</given-names>
</name>
<name>
<surname>de la Calzada</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Casellas</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Brain mapping analysis in patients with hepatic encephalopathy</article-title>. <source>Brain Topogr</source> <year>1990</year>; <volume>2</volume>: <fpage>221</fpage>–<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr36-0960327112456312">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kullmann</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hollerbach</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lock</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Holstege</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Brain electrical activity mapping of EEG for the diagnosis of (sub)clinical hepatic encephalopathy in chronic liver disease</article-title>. <source>Eur J Gastroenterol Hepatol</source> <year>2001</year>; <volume>13</volume>: <fpage>513</fpage>–<lpage>522</lpage>.</citation>
</ref>
<ref id="bibr37-0960327112456312">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hermenegildo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Marcaida</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Montoliu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Grisolia</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>NMDA receptor antagonists prevent acute ammonia toxicity in mice</article-title>. <source>Neurochem Res</source> <year>1996</year>; <volume>21</volume>: <fpage>1237</fpage>–<lpage>1244</lpage>.</citation>
</ref>
<ref id="bibr38-0960327112456312">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chamuleau</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Deutz</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>de Haan</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>van Gool</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Correlation between electroencephalographic and biochemical indices in acute hepatic encephalopathy in rats</article-title>. <source>J Hepatol</source> <year>1987</year>; <volume>4</volume>: <fpage>299</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr39-0960327112456312">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amodio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gatta</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Neurophysiological investigation of hepatic encephalopathy</article-title>. <source>Metab Brain Dis</source> <year>2005</year>; <volume>20</volume>: <fpage>369</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr40-0960327112456312">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunter</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>GB</given-names>
</name>
</person-group>. <article-title>Recovery of awareness after hyperacute hepatic encephalopathy with “flat” EEG, severe brain edema and deep coma</article-title>. <source>Neurocritical Care</source> <year>2010</year>; <volume>13</volume>: <fpage>247</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr41-0960327112456312">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frühauf</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Radunz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Grabellus</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Laube</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Neuromonitoring in a porcine model of acute hepatic failure</article-title>. <source>Lab Anim</source> <year>2011</year>; <volume>45</volume>: <fpage>174</fpage>–<lpage>178</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>